723280-98-6

Usage

Uses

Used in Organic Synthesis:
7-bromo-4-chloro-3-nitroquinoline is utilized as a key intermediate in the synthesis of various biologically active compounds. Its functional groups and structural features make it a valuable component in the creation of complex organic molecules with potential applications in different fields.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 7-bromo-4-chloro-3-nitroquinoline is employed as a precursor for the development of new drugs. Its unique structure and functional groups allow for the design of molecules with specific therapeutic properties, contributing to the advancement of drug discovery and the creation of novel pharmaceutical agents.
Used in Agrochemicals:
7-bromo-4-chloro-3-nitroquinoline also finds application in the agrochemical sector, where it serves as an intermediate in the production of pesticides and other agricultural chemicals. Its reactivity and functional groups enable the synthesis of compounds with targeted biological activity, enhancing crop protection and management strategies.
Used in Research and Development:
Due to its distinctive structure and functional groups, 7-bromo-4-chloro-3-nitroquinoline is an important target for research in drug discovery. Scientists and researchers explore its potential applications, interactions, and mechanisms of action to uncover new avenues for therapeutic intervention and chemical innovation.

InChI:InChI=1/C9H4BrClN2O2/c10-5-1-2-6-7(3-5)12-4-8(9(6)11)13(14)15/h1-4H

Upstream product

• 82121-06-0 4-hydroxy-7-bromoquinoline 
• 723280-94-2 7-bromo-3-nitroquinolin-4-ol 

Downstream Products

• 723283-76-9 (7-bromo-3-nitroquinolin-4-yl)cyclohexylmethylamine 
• 723284-13-7 tert-butyl {4-[(7-bromo-3-nitroquinolin-4-ylamino)methyl]benzyl}carbamate 
• 879004-36-1 N-benzyl-7-bromo-3-nitroquinolin-4-amine 

Relevant academic research and scientific papers

NLRP3 MODULATORS

The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF

The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention o

IMMUNOCONJUGATES TARGETING HER2

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 ("HER2") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

MACROMOLECULE-SUPPORTED TLR AGONISTS

The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule- supported compounds.

IMMUNOCONJUGATES TARGETING PD-L1

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

IMMUNOCONJUGATES TARGETING CEA

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen ("CEA") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

IMMUNOCONJUGATES

The invention provides an immunoconjugate comprising (a) an antibody construct comprising (i) an antigen binding domain and (ii) an Fc domain and (b) 1-8 adjuvant cores, wherein each adjuvant core is covalently bonded to the antibody construct via a linker, wherein each adjuvant core comprises a 2-amino nitrogen moiety with a pendant nitrogen atom and a point of attachment of the linker to the adjuvant core, and wherein the distance between the pendant nitrogen atom and the point of attachment of the linker is greater than about 5 ?. The invention also provides methods for treating cancer with the immunoconjugates.

SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/ or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

NLRP3 MODULATORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES

Imidazoquinoline and imidazonaphthyridine compounds having a nitrogen-containing heterocyclyl substituent at the 5-, 6-, 7-, or 8-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.